{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:50:13Z","timestamp":1791561013474,"version":"4.3.4"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Janssen-Cilag GmbH Neuss","award":["IIS-NIS\/CNTO1275UCO4002"],"award-info":[{"award-number":["IIS-NIS\/CNTO1275UCO4002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world evidence studies of ustekinumab (UST) in ulcerative colitis (UC) are needed because randomized controlled trials do not represent unselected patient populations in everyday clinical practice. Patients with UC were recruited when starting biologic therapy for the first time or switching to a new biologic therapy. This study assessed the effectiveness of maintenance therapy with UST in comparison to anti-TNF or vedolizumab (VDZ) at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between 2020 and 2022, 507 UC patients starting biologic therapy for the first time or switching to a new biologic therapy were enrolled at 34 inflammatory bowel disease (IBD)-specialized centers in Germany. After excluding patients receiving other biologics or small molecules, as well as those with stomas or missing outcomes, the final sample consisted of 476 patients. The outcomes were clinical response, clinical remission (CR), and steroid-free remission. Propensity score (PS) adjustment with inverse probability of treatment weighting was used to reduce the effect of confounding due to physician selection of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 476 patients with UC were included in the analysis (UST: 147, anti-TNF: 168, VDZ: 161). Treatment persistence over 12 months differed significantly (P\u2005&amp;lt;\u2005.001) between UST (93.9%), VDZ (87.0%), and anti-TNF (75.0%). The PS-weighted effectiveness of UST in the mITT analysis at month 12 was not significantly different from anti-TNF or VDZ (CR: UST 26.9%, anti-TNF 34.7%, VDZ 40.9%; P\u2005=\u2005.063).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the prospective RUN-UC study with PS-weighted groups, UST showed higher treatment persistence but no significant difference in maintenance effectiveness compared to anti-TNF or VDZ in UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf052","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T02:45:28Z","timestamp":1742697928000},"source":"Crossref","is-referenced-by-count":8,"title":["Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC study"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2016-6991","authenticated-orcid":false,"given":"Bernd","family":"Bokemeyer","sequence":"first","affiliation":[{"name":"Interdisciplinary Crohn Colitis Centre Minden , Minden ,","place":["Germany"]},{"name":"Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein , Kiel ,","place":["Germany"]},{"name":"Competence Network IBD , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Plachta-Danielzik","sequence":"additional","affiliation":[{"name":"Competence Network IBD , Kiel ,","place":["Germany"]},{"name":"Institute of Human Nutrition and Food Science, Kiel University , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gilman","sequence":"additional","affiliation":[{"name":"Competence Network IBD , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9830-9126","authenticated-orcid":false,"given":"Stefanie","family":"Howaldt","sequence":"additional","affiliation":[{"name":"Research Institute for IBD-HaFCED , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Mohl","sequence":"additional","affiliation":[{"name":"Centre for Gastroenterology Saar MVZ , Saarbr\u00fccken ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Efken","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Minden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ehehalt","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kahl","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krause","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Kassel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Trentmann","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Bremen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"L\u00fcgering","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , M\u00fcnster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Schnoy","sequence":"additional","affiliation":[{"name":"III. Medical Clinic, University Hospital Augsburg , Augsburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Jochum","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9 University Hospital Berlin, Campus Mitte , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Minden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein , Kiel ,","place":["Germany"]},{"name":"Competence Network IBD , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"2025060311000601800_CIT0001","first-page":"123","article-title":"The diagnosis and treatment of Crohn\u2019s disease and ulcerative colitis","volume":"106","author":"Baumgart","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"2025060311000601800_CIT0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","article-title":"Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health","volume":"61","author":"Peyrin-Biroulet","year":"2012","journal-title":"Gut."},{"key":"2025060311000601800_CIT0003","first-page":"300","article-title":"Measuring disability in IBD: the IBD disability index","volume":"9","author":"Colombel","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025060311000601800_CIT0004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000360720","article-title":"IBD therapy: new targets and unmet needs","volume":"79","author":"Colombel","year":"2014","journal-title":"Nestle Nutr Inst Workshop Ser"},{"key":"2025060311000601800_CIT0005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.drudis.2015.07.005","article-title":"Addressing unmet needs in inflammatory bowel disease","volume":"20","author":"Bokemeyer","year":"2015","journal-title":"Drug Discov Today."},{"key":"2025060311000601800_CIT0006","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"2025060311000601800_CIT0007","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"key":"2025060311000601800_CIT0008","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12876-022-02347-1","article-title":"Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"22","author":"Peyrin-Biroulet","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"2025060311000601800_CIT0009","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3748\/wjg.v24.i23.2457","article-title":"Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence","volume":"24","author":"Scribano","year":"2018","journal-title":"World J Gastroenterol."},{"key":"2025060311000601800_CIT0010","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/ecco-jcc\/jjw068","article-title":"Effectiveness research in inflammatory bowel disease: a necessity and a methodological challenge","volume":"10","author":"Salleron","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2025060311000601800_CIT0011","doi-asserted-by":"crossref","first-page":"245","DOI":"10.14740\/gr1194","article-title":"Comparative effectiveness of ustekinumab versus adalimumab in induction of clinical response and remission in Crohn\u2019s disease: experience of a real-world cohort at a tertiary care inflammatory bowel disease referral center","volume":"12","author":"Ahmed","year":"2019","journal-title":"Gastroenterol Res."},{"key":"2025060311000601800_CIT0012","doi-asserted-by":"crossref","first-page":"17562848211010668","DOI":"10.1177\/17562848211010668","article-title":"Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience","volume":"14","author":"Macaluso","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025060311000601800_CIT0013","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3390\/jcm13051519","article-title":"Ustekinumab in the treatment of inflammatory bowel diseases: evolving paradigms","volume":"13","author":"Mocci","year":"2024","journal-title":"J Clin Med"},{"key":"2025060311000601800_CIT0014","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/ecco-jcc\/jjab070","article-title":"Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025060311000601800_CIT0015","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/apt.16544","article-title":"Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study","volume":"54","author":"Fumery","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311000601800_CIT0016","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.15717","article-title":"Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study","volume":"51","author":"Amiot","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311000601800_CIT0017","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1080\/14712598.2021.1981855","article-title":"One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy","volume":"21","author":"Chiappetta","year":"2021","journal-title":"Expert Opin Biol Ther."},{"key":"2025060311000601800_CIT0018","doi-asserted-by":"crossref","first-page":"otab002","DOI":"10.1093\/crocol\/otab002","article-title":"Real-world effectiveness and safety of ustekinumab for ulcerative colitis from 2 tertiary IBD centers in the United States","volume":"3","author":"Hong","year":"2021","journal-title":"Crohns Colitis 360."},{"key":"2025060311000601800_CIT0019","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/flgastro-2022-102168","article-title":"Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study","volume":"13","author":"Honap","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"2025060311000601800_CIT0020","first-page":"349","article-title":"P325 real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a multi-centre study","volume":"15","author":"Parakkal","year":"2021","journal-title":"JCC."},{"key":"2025060311000601800_CIT0021","first-page":"490","article-title":"Ustekinumab for ulcerative colitis: a real-world experience retrospective data analysis of the IBD Cohort Ordensklinikum Linz","volume":"9","author":"Ecker","year":"2021","journal-title":"United Eur Gastroenterol J."},{"key":"2025060311000601800_CIT0022","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/ecco-jcc\/jjac067","article-title":"Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis","volume":"16","author":"Alsoud","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025060311000601800_CIT0023","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ueg2.12275","article-title":"Ustekinumab treatment in ulcerative colitis: real-world data from the Swedish Inflammatory Bowel Disease Quality Register","volume":"10","author":"Thunberg","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"2025060311000601800_CIT0024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/2050640619895361","article-title":"Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis","volume":"8","author":"Ochsenkuhn","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2025060311000601800_CIT0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/00365521.2023.2278427","article-title":"Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a Spanish open-label cohort","volume":"59","author":"Iborra","year":"2024","journal-title":"Scand J Gastroenterol."},{"key":"2025060311000601800_CIT0026","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/ibd\/izac275","article-title":"Efficacy, effectiveness, and safety of ustekinumab for the treatment of ulcerative colitis: a systematic review","volume":"30","author":"Gisbert","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311000601800_CIT0027","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/apt.17386","article-title":"Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis","volume":"57","author":"Taxonera","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311000601800_CIT0028","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1080\/00365521.2022.2095668","article-title":"Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study","volume":"57","author":"Meyer","year":"2022","journal-title":"Scand J Gastroenterol."},{"key":"2025060311000601800_CIT0029","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ecco-jcc\/jjae063","article-title":"Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"18","author":"Fumery","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025060311000601800_CIT0030","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ibd\/izy322","article-title":"Treatment persistence of infliximab versus adalimumab in ulcerative colitis: a 16-year single-center experience","volume":"25","author":"Pouillon","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311000601800_CIT0031","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl19433","article-title":"Comparison of long-term outcomes of infliximab versus adalimumab treatment in biologic-naive patients with ulcerative colitis","volume":"15","author":"Lee","year":"2021","journal-title":"Gut Liver"},{"key":"2025060311000601800_CIT0032","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.dld.2018.06.008","article-title":"A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis","volume":"50","author":"Renna","year":"2018","journal-title":"Dig Liver Dis."},{"key":"2025060311000601800_CIT0033","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.dld.2020.06.014","article-title":"A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis","volume":"52","author":"Macaluso","year":"2020","journal-title":"Dig Liver Dis."},{"key":"2025060311000601800_CIT0034","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cgh.2020.10.003","article-title":"Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis","volume":"20","author":"Lukin","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311000601800_CIT0035","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/ibd\/izz057","article-title":"Comparative efficacy of vedolizumab and adalimumab in ulcerative colitis patients previously treated with infliximab","volume":"25","author":"Favale","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311000601800_CIT0036","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.17616","article-title":"Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: a two-year propensity-score-adjusted analysis from the prospective, observational VEDO(IBD) study","volume":"58","author":"Bokemeyer","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311000601800_CIT0037","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1055\/a-2271-0994","article-title":"Aktualisierte S3-leitlinie colitis ulcerosa (Version 6.2)","volume":"62","author":"Kucharzik","year":"2024","journal-title":"Z Gastroenterol."},{"key":"2025060311000601800_CIT0038","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025060311000601800_CIT0039","first-page":"567","volume-title":"Statistical Power Analysis for the Behavioral Sciences.","author":"Cohen","year":"1988"},{"key":"2025060311000601800_CIT0040","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics f\u00fcr comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Statist Med."},{"key":"2025060311000601800_CIT0041","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference","volume":"15","author":"Ho","year":"2007","journal-title":"Polit Anal."},{"key":"2025060311000601800_CIT0042","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol."},{"key":"2025060311000601800_CIT0043","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcome Res Methodol."},{"key":"2025060311000601800_CIT0044","first-page":"Paper 312","article-title":"Handling missing data by maximum likelihood","volume":"2012","author":"Allison","year":"2012","journal-title":"SAS Global Forum"},{"key":"2025060311000601800_CIT0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2025060311000601800_CIT0046","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med."},{"key":"2025060311000601800_CIT0047","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10464-013-9604-4","article-title":"Drawing causal inferences using propensity scores: a practical guide for community psychologists","volume":"52","author":"Lanza","year":"2013","journal-title":"Am J Community Psychol."},{"key":"2025060311000601800_CIT0048","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ibd\/izad138","article-title":"Real-world effectiveness of vedolizumab vs anti-TNF in biologic-naive Crohn\u2019s disease patients: a 2-year propensity-score-adjusted analysis from the VEDOIBD-Study","volume":"30","author":"Bokemeyer","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311000601800_CIT0049","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1745-6215-12-58","article-title":"Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study","volume":"12","author":"Montedori","year":"2011","journal-title":"Trials"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf052\/62786248\/jjaf052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf052\/62786248\/jjaf052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf052\/62786248\/jjaf052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:01:13Z","timestamp":1748948473000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf052\/8098068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf052","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,27]]},"article-number":"jjaf052"}}